Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:KNSA NASDAQ:NAMS NASDAQ:NRIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.77-5.7%$6.88$4.25▼$9.85$2.66B0.481.98 million shs3.16 million shsKNSAKiniksa Pharmaceuticals International$35.77-2.2%$32.03$17.82▼$37.34$2.71B0.2400,652 shs274,228 shsNAMSNewAmsterdam Pharma$24.52+1.7%$23.76$14.06▼$27.35$2.72B-0.01976,589 shs530,046 shsNRIXNurix Therapeutics$8.44-2.7%$10.58$8.18▼$29.56$662.82M2.1741,396 shs1.06 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-1.38%-2.12%-14.03%+25.09%+13.45%KNSAKiniksa Pharmaceuticals International-1.46%-0.03%+9.53%+30.81%+44.73%NAMSNewAmsterdam Pharma-0.29%-3.87%-3.79%+30.45%+51.13%NRIXNurix Therapeutics-4.09%-10.62%-18.05%-23.88%-65.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.77-5.7%$6.88$4.25▼$9.85$2.66B0.481.98 million shs3.16 million shsKNSAKiniksa Pharmaceuticals International$35.77-2.2%$32.03$17.82▼$37.34$2.71B0.2400,652 shs274,228 shsNAMSNewAmsterdam Pharma$24.52+1.7%$23.76$14.06▼$27.35$2.72B-0.01976,589 shs530,046 shsNRIXNurix Therapeutics$8.44-2.7%$10.58$8.18▼$29.56$662.82M2.1741,396 shs1.06 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-1.38%-2.12%-14.03%+25.09%+13.45%KNSAKiniksa Pharmaceuticals International-1.46%-0.03%+9.53%+30.81%+44.73%NAMSNewAmsterdam Pharma-0.29%-3.87%-3.79%+30.45%+51.13%NRIXNurix Therapeutics-4.09%-10.62%-18.05%-23.88%-65.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0032.94% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1715.09% UpsideNAMSNewAmsterdam Pharma 2.90Moderate Buy$41.5569.43% UpsideNRIXNurix Therapeutics 2.88Moderate Buy$29.07244.45% UpsideCurrent Analyst Ratings BreakdownLatest NRIX, KNSA, NAMS, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025NRIXNurix TherapeuticsBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/25/2025NAMSNewAmsterdam PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.008/7/2025NAMSNewAmsterdam PharmaRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$38.00 ➝ $39.007/31/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.00 ➝ $30.007/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $54.007/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.007/17/2025NAMSNewAmsterdam PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$27.007/15/2025NRIXNurix TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$17.00 ➝ $16.007/14/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $34.007/10/2025NRIXNurix TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $26.007/10/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$32.00 ➝ $30.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.26$7.28 per share0.93($0.89) per share-7.61KNSAKiniksa Pharmaceuticals International$423.24M6.26N/AN/A$6.60 per share5.42NAMSNewAmsterdam Pharma$45.56M60.62N/AN/A$8.20 per share2.99NRIXNurix Therapeutics$54.55M11.83N/AN/A$7.44 per share1.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2626.041.45N/A0.99%-852.36%5.25%10/29/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04914.00143.08N/A0.90%1.05%0.80%11/4/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.620.00N/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.610.00N/AN/A-234.57%-45.26%-34.71%10/10/2025 (Estimated)Latest NRIX, KNSA, NAMS, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/10/2025Q3 2025NRIXNurix Therapeutics-$0.84N/AN/AN/A$16.06 millionN/A8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billion7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 million7/9/2025Q2 2025NRIXNurix Therapeutics-$0.79-$0.52+$0.27-$0.52$16.26 million$44.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16NAMSNewAmsterdam PharmaN/A21.0821.08NRIXNurix TherapeuticsN/A6.826.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%KNSAKiniksa Pharmaceuticals International53.95%NAMSNewAmsterdam Pharma89.89%NRIXNurix TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%KNSAKiniksa Pharmaceuticals International53.48%NAMSNewAmsterdam Pharma20.84%NRIXNurix Therapeutics7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.35 million296.39 millionOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableNRIXNurix Therapeutics30076.45 million70.79 millionOptionableNRIX, KNSA, NAMS, and BHC HeadlinesRecent News About These CompaniesNurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)September 12, 2025 | seekingalpha.comNurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)September 12, 2025 | seekingalpha.comNurix Therapeutics (NASDAQ:NRIX) Trading Down 6.5% - What's Next?September 11, 2025 | marketbeat.comNurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeptember 11, 2025 | seekingalpha.comNurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comParkman Healthcare Partners LLC Sells 181,752 Shares of Nurix Therapeutics, Inc. $NRIXSeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Cuts Position in Nurix Therapeutics, Inc. $NRIXSeptember 8, 2025 | marketbeat.comNurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 - SlideshowSeptember 5, 2025 | seekingalpha.comRedmile Group LLC Sells 140,700 Shares of Nurix Therapeutics, Inc. $NRIXSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Has $13.37 Million Stock Position in Nurix Therapeutics, Inc. $NRIXSeptember 4, 2025 | marketbeat.comInvesco Ltd. Has $1.40 Million Stake in Nurix Therapeutics, Inc. $NRIXSeptember 3, 2025 | marketbeat.comNurix Therapeutics, Inc. $NRIX Shares Sold by Driehaus Capital Management LLCSeptember 2, 2025 | marketbeat.com74,060 Shares in Nurix Therapeutics, Inc. $NRIX Purchased by Walleye Capital LLCSeptember 2, 2025 | marketbeat.comNuveen LLC Invests $2.01 Million in Nurix Therapeutics, Inc. $NRIXSeptember 1, 2025 | marketbeat.comNurix Therapeutics, Inc. $NRIX Shares Acquired by Tema Etfs LLCAugust 31, 2025 | marketbeat.comNurix Therapeutics, Inc. $NRIX Shares Acquired by Russell Investments Group Ltd.August 30, 2025 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Stock Rating Upgraded by Baird R WAugust 29, 2025 | marketbeat.comNurix Therapeutics to Participate in Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comNurix Therapeutics, Inc. $NRIX Shares Sold by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comVanguard Group Inc. Acquires 69,856 Shares of Nurix Therapeutics, Inc. $NRIXAugust 28, 2025 | marketbeat.comNurix Therapeutics, Inc. $NRIX Shares Sold by Wellington Management Group LLPAugust 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRIX, KNSA, NAMS, and BHC Company DescriptionsBausch Health Cos NYSE:BHC$6.77 -0.41 (-5.71%) Closing price 03:59 PM EasternExtended Trading$7.01 +0.24 (+3.55%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Kiniksa Pharmaceuticals International NASDAQ:KNSA$35.77 -0.79 (-2.16%) Closing price 04:00 PM EasternExtended Trading$35.76 -0.02 (-0.04%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.NewAmsterdam Pharma NASDAQ:NAMS$24.52 +0.40 (+1.66%) Closing price 04:00 PM EasternExtended Trading$24.52 0.00 (0.00%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Nurix Therapeutics NASDAQ:NRIX$8.44 -0.23 (-2.65%) Closing price 04:00 PM EasternExtended Trading$8.44 0.00 (-0.06%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
